* participant was pregnant, or lactating, or of childbearing potential and not used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female was post-menopausal for at least 1 year or surgically sterile. * receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. * prior administration of a coronavirus vaccine sars-cov-2, sars-cov, middle east respiratory syndrome). * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). * history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically * chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, was at a stage where it might interfere with study conduct or completion. * receipt of any therapy known to had in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood drew. * health care workers provided direct participant care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

* participant was pregnant, or lactating, or of childbearing potential and not used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female was post-menopausal for at least 1 year or surgically sterile. * receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. * prior administration of a coronavirus vaccine sars-cov-2, sars-cov, middle east respiratory syndrome). * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). * history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically * chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, was at a stage where it might interfere with study conduct or completion. * receipt of any therapy known to had in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood drew. * health care workers provided direct participant care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

participant was pregnant, or lactating, or of childbearing potential and not used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female was post-menopausal for at least 1 year or surgically sterile. receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. prior administration of a coronavirus vaccine sars-cov-2, sars-cov, middle east respiratory syndrome). known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, was at a stage where it might interfere with study conduct or completion. receipt of any therapy known to had in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood drew. health care workers provided direct participant care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

participant was pregnant, or lactating, or of childbearing potential and not used an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female was post-menopausal for at least 1 year or surgically sterile. receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which might be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. prior administration of a coronavirus vaccine sars-cov-2, sars-cov, middle east respiratory syndrome). known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, was at a stage where it might interfere with study conduct or completion. receipt of any therapy known to had in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood drew. health care workers provided direct participant care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile - receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines - prior administration of a coronavirus vaccine (severe acute respiratory syndrome coronavirus 2 [sars-cov-2], sars-cov, middle east respiratory syndrome) - known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically - chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion - receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw - health care workers providing direct patient care for covid-19 patients the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile - receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines - prior administration of a coronavirus vaccine (severe acute respiratory syndrome coronavirus 2 [sars-cov-2], sars-cov, middle east respiratory syndrome) - known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - history of sars-cov-2 infection, confirmed either clinically, serologically, or microbiologically - chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion - receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw - health care workers providing direct patient care for covid-19 patients the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.